Efficacy, safety and pharmacokinetic results of a phase III, open-label, multicenter study with a plasma-derived von Willebrand Factor (VWF)/factor VIII (FVIII) concentrate in pediatric patients <12 years of age with hemophilia A (SWIFTLY-HA study) - Djambas Khayat, C; Iosava, G; Romashevskaya, I (J Blood Med, 2021)